<DOC>
	<DOC>NCT02383108</DOC>
	<brief_summary>A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.</brief_summary>
	<brief_title>Strategy for Maintenance of HIV Suppression With Elvitegravir + Darunavir/Ritonavir in Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>HIV1 infected children weighing â‰¥ 17 kg at the screening visit Parents or guardians, and children where appropriate, willing and able to give informed consent and to adhere to the protocol Children must have all HIV1 RNA viral load &lt;50c/mL for at least 12 months with a minimum of two separate results before screening. Children on a 3drug PI/r or NNRTI containing regimen for at least 6 months. Children/parents/guardians prepared to switch if randomised to elvitegravir + darunavir/ritonavir arm Children and parents prepared to restart the current ART regimen after simplification if viral load restart criteria are met (see Section 5.5) For children aged 612 either: children and caregivers are willing to participate in the leadin PK study if the child is aged 612 and the PK study is still enrolling children in their weight band* OR Data from the leadin PK study have been analysed and children aged 612 can be enrolled directly into the main study * only children randomised to Arm 1 will take part Receiving or requiring agents with interactions with darunavir, RTV, or EVG Evidence of resistance to DRV or integrase inhibitors (for participants in clinical sites where resistance testing is standard of care) Previous exposure to integrase inhibitors for more than 2 weeks History of previous encephalopathy Intercurrent illness (randomisation can take place after the illness resolves) Creatinine, AST or ALT of grade 3 or above at screening. Diagnosis of tuberculosis and on antituberculosis treatment (children can be enrolled after successful tuberculosis treatment) Hepatitis B or Hepatitis C coinfection Pregnancy or risk of pregnancy in girls of childbearing potential unless committed to taking effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>